 |
EnteroMedics Announces Closing of $29.8 Million Public Offering of Common Stock and Warrants
Dec 14, 2010
|
13.3 KB |
|
| |
ST. PAUL, Minn.--(BUSINESS WIRE)--
EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices
using neuroblocking technology to treat obesity and other
gastrointestinal disorders, today announced the closing of its
previously announced public offering of 17.02 million shares of the
Company's com...
|
|
EnteroMedics Announces Exercise of Over-Allotment Option Bringing Total Proceeds of Recent Offering to Approximately $29.8 Million
Dec 10, 2010
|
13.8 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 12/10/10 --
EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that the underwriter of its previously announced public offering has exercised in full its over-allotment option to purchase an ad...
|
|
EnteroMedics Announces Pricing of $25.9 Million Public Offering of Common Stock and Warrants
Dec 9, 2010
|
13.7 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 12/09/10 --
EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced the pricing of a public offering for 14.8 million shares of the Company's common stock together with warrants to purchase an addit...
|
|
EnteroMedics Announces Data From Australian Patient Cohort in EMPOWER Study and From Caloric Intake Study
Nov 8, 2010
|
19.0 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 11/08/10 --
EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced clinical results from the Australian patient cohort of its EMPOWER? study and from a caloric intake study of VBLOC® vagal blocking...
|
|
EnteroMedics Inc. Announces Adjournment of Special Stockholder Meeting Until 10:00 a.m. Central Time on October 29, 2010
Oct 22, 2010
|
12.0 KB |
|
| |
ST. PAUL, MN, Oct 22, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that it did not reach a quorum for the special stockholder meeting on Friday, October 22, 2010 and will adjourn th...
|
|
EnteroMedics Reports Third Quarter 2010 Financial Results
Oct 21, 2010
|
16.9 KB |
|
| |
ST. PAUL, MN, Oct 21, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced financial results for the three and nine months ended September 30, 2010.
For the three months ended September...
|
|
EnteroMedics Announces Updated Data from VBLOC-DM2, EMPOWER and VBLOC RF2 Studies
Oct 20, 2010
|
18.1 KB |
|
| |
ST. PAUL, MN, Oct 20, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced updated clinical results, including weight loss, HbA1c and hypertension control data, from the Company's VBLOC-DM2...
|
|
EnteroMedics Completes $6.3 Million Convertible Preferred Stock Offering
Sep 30, 2010
|
13.2 KB |
|
| |
ST. PAUL, MN, Sep 30, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that it has entered into binding securities purchase agreements in a private placement transaction with several ac...
|
|
EnteroMedics Achieves Major Milestones in Global Regulatory and Commercialization Strategy for the Maestro System
Aug 2, 2010
|
16.3 KB |
|
| |
ST. PAUL, MN, Aug 02, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that the Company has received conditional approval for its Investigational Device Exemption (IDE) application with...
|
|
EnteroMedics Reports Second Quarter 2010 Financial Results
Jul 22, 2010
|
15.0 KB |
|
| |
ST. PAUL, MN, Jul 22, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced financial results for the three and six months ended June 30, 2010.
For the three months ended June 30, 2010, ...
|
|
Enteromedics Announces 1-for-6 Reverse Split of Common Stock
Jun 29, 2010
|
12.5 KB |
|
| |
ST. PAUL, MN, Jun 29, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that its Board of Directors has approved a 1-for-6 reverse split of its common stock, to be effective upon the clo...
|
|
Data From EnteroMedics' VBLOC-DM2 ENABLE Study to Be Presented at American Society for Metabolic and Bariatric Surgery Meeting
Jun 22, 2010
|
16.8 KB |
|
| |
ST. PAUL, MN, Jun 22, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that updated clinical results from the Company's VBLOC-DM2 ENABLE (DM2) study will be presented on June 26, 2010 a...
|
|
EnteroMedics Reports First Quarter 2010 Financial Results
Apr 21, 2010
|
14.5 KB |
|
| |
ST. PAUL, MN, Apr 21, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced financial results for the three months ended March 31, 2010.
For the three months ended March 31, 2010, the Co...
|
|
EnteroMedics Extends Neuroblocking Technology Research and Development Collaboration
Mar 17, 2010
|
12.3 KB |
|
| |
ST. PAUL, MN, Mar 17, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that it has extended its 2005 collaboration agreement with the Mayo Clinic for an additional two years. The collab...
|
|
EnteroMedics Announces Submission of IDE Application for Maestro RC System
Mar 15, 2010
|
12.2 KB |
|
| |
ST. PAUL, MN, Mar 15, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that it has submitted an Investigational Device Exemption (IDE) application with the US Food and Drug Administrati...
|
|
EnteroMedics Appoints Dr. Scott Shikora as Consulting Chief Medical Officer
Feb 22, 2010
|
12.9 KB |
|
| |
ST. PAUL, MN, Feb 22, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today the appointment of Scott A. Shikora, M.D., F.A.C.S, as Consulting Chief Medical Officer. Dr. Shikora is currently ...
|
|
EnteroMedics Reports Fourth Quarter and Full Year 2009 Financial Results
Jan 28, 2010
|
16.2 KB |
|
| |
ST. PAUL, Minn., Jan 28, 2010 (BUSINESS WIRE) -- EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices
using neuroblocking technology to treat obesity and other
gastrointestinal disorders, today announced financial results for the
three months and full year ended December 31, 2009.
For the full year 2009, the ...
|
|
EnteroMedics Announces Regulatory Path Forward Following FDA Meeting
Jan 28, 2010
|
12.9 KB |
|
| |
ST. PAUL, Minn., Jan 28, 2010 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM),
the developer of medical devices using neuroblocking technology to treat
obesity and other gastrointestinal disorders, announced today that,
following a recent meeting with the U.S. Food and Drug Administration
(FDA) to discuss the Com...
|
|
EnteroMedics Announces Transfer of its Common Stock to the Nasdaq Capital Market
Jan 21, 2010
|
12.7 KB |
|
| |
ST. PAUL, Minn., Jan 21, 2010 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, announced today that it has received approval from the Nasdaq
Stock Market Listing Qualifications Staff to transfer the list...
|
|
EnteroMedics Announces $4.8 Million Financing
Jan 14, 2010
|
12.9 KB |
|
| |
ST. PAUL, Minn., Jan 14, 2010 (BUSINESS WIRE) -- EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices
using neuroblocking technology to treat obesity, its associated
co-morbidities, and other gastrointestinal disorders, today announced
that it has entered into a definitive agreement with institutional
...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
